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Background. Although specific guidelines for the treatment of hypercholesterolemia have been published, it is not known whether physicians treating patients likely to have lipid disorders have adopted the recommendations.
Methods and Results. The approach of cardiologists to the treatment of hypercholesterolemia in a metropolitan teaching hospital was assessed by interviewing patients with chest pain who were admitted for coronary angiography in [1988] [1989] and by measuring fasting blood lipid profiles. At 1 month and again 12-24 months later, patients were contacted by telephone to determine if there had been any changes in treatment. Of 95 patients evaluated, 81 had coronary artery disease. Only 17% of those with high levels of total cholesterol and/or low density lipoprotein cholesterol were being actively treated with diet and/or drugs. In the remaining patients, either lipid studies had not been done or abnormal results had not been addressed. There was little change in treatment approach during the month after the diagnostic procedure. Furthermore, the experience was similar in those patients subjected to coronary revascularization. One to 2 years after the initial intervention, 69 of the original study group could be contacted again. Although active dietary or pharmacological therapy was initiated in some individuals during this interval, it was stopped in others. Thirty-five percent of hypercholesterolemic patients were receiving targeted therapy.
Conclusions. Thus, only a small proportion of patients with documented coronary artery disease and hypercholesterolemia were being actively treated for their lipid disorder, suggesting that the published treatment guidelines have not yet been fully accepted. However, an encouraging improvement in frequency of treatment of hypercholesterolemia was documented during the 1-2-year observation period.(Circulation 1991;83:1294-1304) I ntensive efforts have been made to identify risk factors for atherosclerosis in hopes that the disease itself could be prevented or at least attenuated. Genetic,' experimental,2'3 epidemiological,4-19 and interventional20-32 studies have established that an elevated blood cholesterol level is a major cause of peripheral vascular and coronary artery disease and that lowering of elevated levels will result in a reduction of the risk of myocardial infarction and death related to cardiovascular dis-ease. These conclusions were echoed in the strong recommendation of two National Institutes of Health (NIH) panels that blood cholesterol levels of the American population must be lowered,33,34 and aggressive treatment guidelines were outlined.34 Furthermore, educational campaigns were initiated to instruct the populace as well as physicians. 35 Despite the existing data linking serum cholesterol levels and cardiovascular morbidity and mortality, the documented approaches of many physicians, whether old36-41 or young,36-43 medical school faculty37, 39, 41, [44] [45] [46] or private practitioners, 36, 38, 40, 42, 43, [47] [48] [49] [50] [51] [52] [53] to hypercholesterolemia in their patients have often fallen short of the recommendations of the NIH panel. 34 If attempts to lower the cholesterol level of the populace are to succeed, family practice doctors and general practitioners will have to become part of the solution. However, practices are difficult to change. Therefore, it would be advantageous to have one specialty group that might spearhead the campaign. The demonstration of one group's acceptance of the campaign's principles and aggressive treatment might encourage others to follow. Cardiologists would be a likely selection. They are called on daily to deal with the ravages of coronary artery disease, and they have been bombarded with the cholesterol doctrine for longer periods than others. It would seem reasonable to expect cardiologists to be in the forefront of the professional community seeking to promote such preventive medicine measures aimed at diminishing the prevalence of coronary artery disease. To evaluate the current position of cardiologists, their approach to screening for and treatment of blood lipid abnormalities at a major teaching hospital in a large metropolitan area was studied.
Methods
To determine the prevailing treatment of lipid disorders by cardiologists admitting patients to Montefiore Medical Center, an 800-bed tertiary care facility in New York City, patients were selected from those referred from March 1988 to March 1989 for elective coronary angiography for the evaluation of chest pain. No patient had been hospitalized during the 2 months preceding the procedure, and all were free of other systemic illnesses causing fluctuations in weight, changes in dietary intake, alteration of sense of well-being, or debilitation. Attempts were made to include all patients meeting these criteria in the evaluation, but some were missed because of the limitations imposed by the work schedules of the investigators. Therefore, 95 of 138 individuals meeting the entry criteria were actually included in the study. However, demographic and cardiac catheterization data in the 43 patients not enrolled were not different from those of the 95 subjects entered in the study. All patients were interviewed on admission to determine their awareness of prior risk factor evaluation and of the nature of any interventions or therapy initiated by their cardiologist or other medical personnel. A standardized questionnaire was used basically to determine whether the patient had hypertension or diabetes, whether the serum cholesterol level was known, and what the referring physician had said about any lipid abnormality or possible therapy. Emphasis was placed on eliciting a history of treatment of blood lipid abnormalities. On the basis of this interview, patients were placed into one of five groups. Group 1 patients were unaware that any testing of blood lipids had ever been done. Group 2 patients claimed that their doctors had said that their blood tests were normal. Subjects in group 3 were aware of an abnormality of blood lipids but were given only some vague advice by their physicians. In these instances, the physician was likely to have merely suggested that the patient adopt a low cholesterol diet without offering any specific guidelines or advice about how to achieve this goal. Patients in group 4 had been counseled and given detailed literature on diets by the physician or had been referred to a dietitian to help correct the lipid problem. Finally, patients in group 5 had been started on pharmacological therapy. Therefore, only in groups 4 and 5 had the physician actively intervened to correct a documented blood lipid abnormality.
Patients in all groups were fasted the night before angiography. After transport of patients to the cardiac catheterization laboratory but before insertion of catheters or administration of any drugs including heparin, 10 ml blood was collected for measurement of serum total cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels by the hospital chemistry lab. Serum cholesterol values were always posted in the patient's chart within 24 hours. The other results were available within 2-3 days and were then inserted into the chart or were accessible by computer terminal if the patient had been discharged. At the time of discharge, all charts were reviewed to determine whether the referring physician had made note of any abnormal blood lipid determinations and whether any therapeutic measures had been contemplated. Also, all diet orders were reviewed. One month after the diagnostic catheterization procedure, all patients were contacted by telephone to determine whether there had been any change in treatment of possible lipid abnormalities. An interview format similar to that used during the initial contact was used. Again, 12-24 months after the initial cardiac catheterization, attempts were made to contact all patients to determine whether their knowledge of their condition had changed and whether any additional interventions had been initiated. Particular attention was paid to a review of all pharmacological agents being taken.
Total cholesterol was measured enzymatically by an automated analyzer. 54 The HDL cholesterol fraction was similarly measured enzymatically after precipitation of other lipoproteins by buffered phosphotungstic acid-n-hydrate. 55 
Results
Of 95 patients entered into the study, 58.6% had been referred to the admitting cardiologist for the express purpose of evaluation for coronary angiography, whereas 41.4% had been followed up and treated by the cardiologist for varying time periods before cardiac catheterization. Of the total group, 19% were admitted by four full-time faculty members, 8% by cardiology fellows, and the remaining 73% by 12 cardiology groups or practicing cardiologists. Of the 12 private cardiology groups or individuals, five admitted at least eight patients during the year of observation. One subject died 2 weeks after cardiac catheterization and is not considered further. Because of the potential problem of laboratory error in the measurement of serum lipid levels, a comparison was made between the cholesterol level measured in the blood obtained in the cardiac catheterization laboratory and a random cholesterol level determined as part of the routine admission blood chemistry screening in the patients. There was remarkable agreement between the two values; the average difference was only 3.6% (range, 1.1-7.5%).
Thirteen individuals had normal coronary arteries, and four of these had total cholesterol levels that exceeded 240 mg%. The remaining 81 subjects had obstructive coronary artery disease with at least a 50% luminal narrowing of one coronary artery. Table  1 summarizes data for this group with obstructed vessels. The average age of patients in each of the five groups ranged from 54.5 to 62.0 years. There were 21 women and 60 men. Most groups had an average of two obstructed coronary arteries. Only in group 5 patients on drug therapy was there a tendency for more widespread involvement. Serum total cholesterol ranged from 144 to 503 mg%, and LDL cholesterol ranged from 64 to 401 mg% at the time of initial testing. In group 1 patients without knowledge of prior testing, serum cholesterol averaged 242 mg%. In patients who were told that their blood lipids were normal (group 2), average serum cholesterol was 218 mg%, although nine of the 24 patients in this group had serum cholesterol levels in excess of 240 mg%. The average serum cholesterol in patients who were told that there was an abnormality but in whom little was done (group 3) was 255 mg%. In patients on a prescribed diet (group 4), the serum cholesterol averaged 240 mg%, whereas it was 214 mg% in those on targeted drug therapy (group 5). Serum LDL cholesterol data showed a similar pattern, whereas serum HDL cholesterol levels varied little among groups.
The threshold for treatment of blood lipid abnormalities continues to evolve. Figure 1 depicts considered to be 200 mg% as suggested by the National Cholesterol Education Program,34 then 60 individuals had abnormally elevated cholesterol levels, but only nine patients (15.0%) were in groups 4 or 5.
LDL cholesterol data are presented in Figure 2 . If the threshold level is considered to be 160 mg%, then only 18.8% of the 32 individuals with elevated levels were being treated with diet and/or drugs. With a threshold level of 130 mg%, cardiologists were actively treating only 14.0% of 57 with high levels. Of particular note is the absence of treatment of the patient with an LDL cholesterol level of 401 mg% and a total cholesterol level of 503 mg%.
To determine whether results of the cardiac catheterization and documentation of significant coronary artery obstructive lesions would alter the approach of the referring cardiologists to treatment of the lipid disorders, regimens before and after the catheterization were compared. Figure 3 demonstrates that at the time of cardiac catheterization 17.3% of the subjects with proven coronary disease were in groups 4 and 5. One month later, there was a small improvement, when 25.9% of the study group were being actively treated. There was very little movement between groups. In Figure 4, with more restrictive treatment threshold levels of 200 mg% for total cholesterol and 130 mg% for LDL cholesterol (i.e., those recommended by the National Cholesterol Education Program34), only 11 of 61 (18.0%) of those needing treatment were receiving it at the time of the cardiac catheterization ( Figure 4 , right panel). Again, 4 weeks later, there were only eight additional patients who received treatment; one patient was moved from a treatment group to one of the nontreatment groups.
Because of the possibility that the patients' recollections of events occurring 1 month earlier during a hospitalization might be unclear, all charts were reviewed for possible indications of intended therapy of lipid abnormalities. Despite the posting of abnormal blood cholesterol results in all patient charts within 24 hours of admission, infrequently were results commented on in the progress notes, and rarely were treatment plans apparent. Furthermore, a consultation for nutritional instruction was never found. Group During the 1-2-year interval after the initial telephone contact, two additional individuals had coronary angioplasty, and two had surgical revascularization. One individual in each category was being treated with lipid-lowering drugs by the time of the 1 mo p cath second telephone contact. However, one individual was not being treated after angioplasty, and one was not being treated after surgical revascularization (serum cholesterol, 273 and 268 mg%, respectively).
Discussion
The effects of an elevated serum cholesterol level on vascular disease have been debated for many decades. Attempts by a few to publicize the merits of lowering blood lipid levels of Americans have been met with some success. In the past 25 years, serum cholesterol levels in the population have actually declined by 6-15 mg%, perhaps contributing to the welcome diminution in the annual mortality rate for cardiovascular disease. [59] [60] [61] [62] Because lowering of serum cholesterol by either dietary or pharmacological measures has resulted in concomitant falls in occurrence rates of nonfatal myocardial infarctions and death attributed to cardiovascular causes,63,64 an NIH Expert Panel established an aggressive treatment protocol in an attempt to substantially lower the serum cholesterol level of the American population34 and embarked on an education campaign to alert both the public and the medical community to the benefits of evaluation of blood cholesterol status and treatment of levels above cited threshold values.35 Random surveys of the general public in 1983 before and again in 1986 after initiation of the public education campaign have revealed a surprisingly high baseline awareness of the importance of serum and dietary cholesterol, with further improvement after concerted attempts at publicization of the campaign. 65 The attitude of the public is exemplified by the enthusiastic response to announcements for mass cholesterol-screening projects. 48 With several notable exceptions,536667 surveys of medical practitioners before and again after announcement of the NIH guidelines and initiation of the educational campaign have revealed a continuing uncertainty regarding serum cholesterol as an important risk factor for coronary artery disease36,38,4352 and a failure both to screen patients for blood lipid abnormalities42-44,52,68 and to treat high serum cholesterol levels.4348,4951 Hypercholesterolemia has been overlooked in hospitalized patients with both overt heart disease and clinically normal hearts37,41,44-46 and may be untreated when individuals identified as having high blood cholesterol levels during mass screenings present to their physicians.48-51 When treatment is initiated, the threshold levels of cholesterol are significantly higher38,40,53 than those recommended by the NIH panel. 34 The approaches of practicing cardiologists admitting patients to a New York City hospital have been evaluated in the present study not with mailed questionnaires but with a prospective analysis of the adequacy of treatment of lipid disorders in their patients. The average age in the five patient groups ranged from 54.5 to 62.0 years ( Because the initial evaluation of the subjects selected for this study began only 2 months after publication of the complete guidelines of the NIH Expert Panel,34 it was considered possible that slow dissemination of the information might have explained the initial absence of aggressive treatment of hyperlipidemia. Therefore, attempts to contact all patients at least 1 and up to 2 years after their cardiac catheterization were made. Information could not be obtained for nine patients, two of whom were being treated pharmacologically at the time of the 1-month follow-up. It is striking that only 35% of the contacted patients with documented hyperlipidemia were being actively treated with diet and/or drugs more than 2 years after publication of the NIH guidelines34 and at least 1 year after this study's preliminary data obtained at cardiac catheterization and the 1-month follow-up were presented to the hospital's attending cardiologists as well as internists. It is also noteworthy that even some hyperlipidemic individuals undergoing coronary revascularization were still not being treated.
Although only 40% of the study subjects undergoing coronary angiography were long-term patients of the admitting cardiologists, the rate of initial treatment of their patients by these specialists was To achieve more optimal treatment of hyperlipidemic disorders, a more intensive educational thrust is required.18,526' Physicians, including cardiologists, must be made to appreciate the benefits of low blood cholesterol levels. Physicians in Massachusetts81 and Richmond, Virginia,79 welcome continuing medical education programs as a vehicle for transfer of information; others value programs established by professional societies. 79 The Minnesota Heart Health Program has been very successful in increasing the understanding of local medical personnel, encouraging their participation in treatment of their patients, and raising the consciousness of public health officials.52 Additional emphasis must be placed on this issue in medical school and house staff training programs.82 It is gratifying to realize that some of these educational efforts have indeed produced an increased awareness of the cholesterol problem. Thus, in Schucker's report38 of physician surveys done in 1983 and again in 1986, there was a significant and encouraging decrease in threshold levels at which physicians would treat hypercholesterolemia. However, cardiologists were not much different from internists. The present data also suggest an encouraging trend. By the time of the second telephone contact, virtually all patients knew that their serum cholesterol had been tested. Furthermore, the proportion of patients with hyperlipidemia receiving specific treatment increased from 17% at the time of cardiac catheterization to 25% after 1 month to 35% 1-2 years later. However, the upward trend is only a modest one and underscores the need for intensive education for cardiologists as well as internists and family practitioners. Undoubtedly, in areas such as Framingham, Massachusetts, where epidemiological studies have been conducted, physicians are likely to be keener about treatment of hypercholesterolemia. But involvement of physicians probably quickly fades as their distance from these centers increases. However, even if all physicians believed in the merits of lowering serum cholesterol levels, the program cannot be successful unless some of the more mundane difficulties already noted are addressed. For example, the physician probably requires the assistance of a "prevention nurse," counselor, or dietitian who has been suitably trained to discuss with patients lifestyle changes, including diet, and who can clarify and amplify the physician's message, encourage the patient, provide necessary feedback, and follow his/her progress.52,83-85 Such a person clearly would find a ready niche in the cardiologist's office and probably also in the office of the generalist, who undoubtedly sees many individuals with asymptomatic hyperlipidemia. Financial issues still remain to be resolved but should not prevent the medical community from instituting needed patient care.
